Time to death among men with nmCRPC by NCCN risk group

One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …

Numbers progressing and time to progression on active surveillance

A new study just published in the World Journal of Urology has provided us with data from the Prostate Cancer Outcomes Registry — Victoria (in Australia) on the progression of men initially managed on active surveillance. … READ MORE …

Now here’s a REALLY unsurprising piece of news!

A new report in the journal JAMA Oncology is said to have detailed “the psychological damage” that a cancer diagnosis “often leaves in its wake for patients.” … READ MORE …

Long-term quality of life for men on active surveillance

According to a paper presented today at the annual meeting of the European Association of Urology (EAU) in Munich, Germany, men on a structured active surveillance (AS) protocol have a high, long-term quality of life on follow-up. … READ MORE …

How long is long enough? Length of follow-up on clinical trials for primary treatments

Many of us are faced with the difficulty of choosing a primary therapy based on data from clinical trials with follow-up shorter than our life expectancy. How can we know what to expect in 20 or 30 years? … READ MORE …

Trends in the management of localized prostate cancer: 2000 to 2010

The international trend back toward increased use of more conservative management techniques (e.g., active surveillance and watchful waiting) for men with low-risk disease is again indicated in data from the Anglian region of the National Health Service in the UK. … READ MORE …

Survival times among men with biochemically recurrent prostate cancer

It would hardly come as a shock to most experienced prostate cancer advocates and patients to learn that there is an association between survival time and the aggressiveness of a patient’s cancer at the time of diagnosis if that cancer progresses. … READ MORE …